BRCA1 and neoplasm: The fact that the BRCT domains are frequently targeted by many clinically important mutations and most of these mutations disrupt the binding surface of the BRCT domains to phosphorylated peptides indicates that they are integral for BRCA1's tumor suppressor function [31].